Hyderabad-based Intonation Research Laboratories has announced a collaboration with Stanford University’s Innovative Medicines Accelerator (IMA) to develop innovative treatments for cancer. The partnership aims to reduce the time and resources required to translate biomedical breakthroughs into clinically and commercially viable medicines. Dr. Suresh K. Jain, founder and Chairman of Intonation, stated that the collaboration with Stanford University will enhance the drug discovery ecosystem in India and create cost-effective treatments for neuroendocrine tumors.
Stanford University President, Marc Tessier-Lavigne, expressed excitement about the collaboration, highlighting its potential to accelerate the translation of promising research into new therapies. The goal of the collaboration is to connect biomedical researchers with partners to efficiently translate Stanford discoveries into impactful treatments for patients. Dr. Justin Annes, an associate professor of endocrinology at Stanford, and Mark Smith, head of medicinal chemistry at Sarafan ChEM-H, will lead the collaborative project with Intonation over the next two years.
Lloyd Minor, Dean of the Stanford School of Medicine, emphasized the aim of the collaboration to improve patient care efficiently. He expressed the hope of delivering transformative treatments to patients with neuroendocrine tumors through an accelerated drug development program. The agreement involves a close partnership where Intonation, the Annes laboratory, and the IMA will contribute expertise and resources to strengthen the intellectual property generated at Stanford University.
Intonation Research Laboratories, founded in 2005, provides contract research services to the global pharmaceutical industry. The company collaborates with academic institutions worldwide to develop innovative product opportunities. With an upcoming move to a new state-of-the-art research center in Cherlapalli, Hyderabad, Intonation aims to further enhance its research capabilities.
Stanford University is renowned for its dedication to research, education, and medical care. Located in the San Francisco Bay Area, the university’s academic health system, Stanford Medicine, includes the Stanford School of Medicine and adult and pediatric healthcare delivery systems. Stanford Medicine integrates research, education, and clinical care to harness the full potential of biomedicine.
In conclusion, the collaboration between Intonation Research Laboratories and Stanford University’s Innovative Medicines Accelerator holds promise for the development of groundbreaking treatments for cancer. With a focus on bringing innovative therapies to patients more efficiently, this collaboration exemplifies the shared goal of advancing medical research and improving patient care.
